The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease.
UACR is a simple test that measures the amount of albumin and creatinine in a person's urine. Albumin is a protein that is normally found in the blood, but can be found in higher concentrations in the urine when the kidneys are not functioning properly. Creatinine is a waste product formed in the body and is normally excreted through the urine. UACR is measured by dividing the amount of albumin present in the urine (measured in milligrams per gram of creatinine) by the amount of creatinine present in the urine (measured in milligrams per gram of creatinine). The result is expressed as a ratio.
UACR is used to detect early signs of kidney damage, as well as to monitor the progression of CKD. UACR can be used to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR can also be used to assess the effectiveness of treatments, such as medications or lifestyle changes, that are used to slow the progression of CKD. UACR is also used to monitor patients who have already been diagnosed with CKD to ensure that their kidney function is not deteriorating further.
The normal range for UACR is 0-30 mg/g. A UACR of 30 mg/g or higher is considered abnormal and may indicate the presence of kidney disease. It is important to note that a UACR of 30 mg/g or higher does not necessarily mean that a person has CKD. UACR can be elevated due to other factors, such as dehydration, infection, or certain medications. Therefore, it is important to consult with a doctor to determine the cause of an elevated UACR.
UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
The Urine Albumin Creatinine Ratio (UACR) is an important indicator of kidney health that is used by doctors to assess the risk of developing chronic kidney disease (CKD). UACR is a measure of the amount of albumin, a protein, that is present in the urine, relative to the amount of creatinine, a waste product formed in the body. UACR is a useful tool for doctors to identify patients who are at risk for developing CKD, as well as those who may already be in the early stages of the disease. UACR testing is recommended for anyone who is at risk for developing CKD, including those with diabetes, hypertension, or a family history of CKD. Additionally, UACR testing is recommended for anyone who is already diagnosed with CKD, to monitor for any changes in kidney function.
1.
A study outlines the need for policies that enhance cancer patients' autonomy and information.
2.
New CAR T-Cell Therapy Approved for Leukemia
3.
The FDA has approved momelotinib for use in myelofibrosis patients who also have anemia.
4.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
5.
Alone for 500 Days, but Never Lonely: The Introvert's Dream.
1.
Precision Oncology: Personalized Medicine Shaping the Future of Cancer Care
2.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
3.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
4.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
5.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
2.
Thromboprophylaxis In Medical Settings
3.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation